US FDA’s Big Transition: Not The Commissioner

US FDA’s Big Transition: Not The Commissioner – The Drug Center

03 Mar 2021

• By Michael McCaughan

It remains uncertain whether Acting Commissioner Woodcock will be nominated for the post. Regardless, the drug center she has run for most of three decades is going to have to adjust to new management.

photo illustration: shutterstock/FDA — Whatever happens in the US FDA commissioner race, it seems likely that the torch is going to be passed for CDER leadership.

The US Food & Drug Administration is facing a most unusual leadership transition with Acting Commissioner Janet Woodcock seemingly undergoing an informal tryout period that could end with her becoming the first career FDA official to be made commissioner since before the Nixon Administration.

Or the apparent opposition to her selection from some Senate Democrats could force the Biden Administration to start over and...